IVT-8086
Solid Tumors (Pediatric Osteosarcoma, Sarcomas, Breast Cancer, Pancreatic Cancer)
Key Facts
About Innova Therapeutics
Innova Therapeutics is a private, preclinical-stage biotech developing a first-in-class monoclonal antibody platform targeting the SFRP2 protein, a novel oncology target linked to poor patient outcomes. The company's lead candidate, IVT-8086, is a humanized mAb being explored as a monotherapy and in combination for difficult-to-treat solid tumors. Led by an experienced team with a successful exit history, Innova is also developing a companion diagnostic for SFRP2 to aid in early detection and prognosis. The company is positioned to address significant unmet needs in oncology, though it faces the inherent risks of novel target validation and early-stage development.
View full company profile